-
Mashup Score: 8
The Ministry of Food and Drug Safety (MFDS) has approved Gilead Sciences’ chimeric antigen receptor T-cell (CAR-T) therapy Yescarta (ingredient: axicabtagene ciloleucel) for the treatment of relap…
Source: www.koreabiomed.comCategories: General Medicine NewsTweet
-
Mashup Score: 8
New treatment option now available across all UK nations
Source: pharmatimes.comCategories: General Medicine NewsTweet-
🚨 News 🚨 The Scottish Medicines Consortium (SMC) approves zanubrutinib for patients with R/R MCL after ≥1 prior line of therapy, based on data from the phase II BGB-3111-206 and the phase I/II BGB-3111-AU-003 trials. Read more: https://t.co/87GozYSU4X #lymphoma #lymsm #MedNews https://t.co/W9mFyhLtiz
-
-
Mashup Score: 0BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia - 18 day(s) ago
Decision highlights the promise of BGB-16673, an investigational and potentially first-in-class BTK degrader designed to overcome resistance and deepen responses in B-cell malignancies SAN CARLOS, Calif.–(BUSINESS WIRE)– $ONC #BeOne — BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to the Company’s investigational Bruton’s tyrosine kinase (BTK) degrader,
Source: www.biospace.comCategories: General Medicine NewsTweet-
🚨 News 🚨 @EMA_News grants priority medicines (PRIME) designation to BGB-16673, an oral BTK degrader, for the treatment of patients with R/R Waldenström macroglobulinemia who were previously treated with a BTKi. Read more: https://t.co/osoyx22axY #lymphoma #lymsm #MedNews https://t.co/2BEseMvHWF
-
-
Mashup Score: 9Ibrutinib granted approval by the EC for patients with previously untreated MCL who would be eligible for auto-HSCT - 26 day(s) ago
On July 23, 2025, the European Commission approved ibrutinib, in combination with chemotherapy, for the treatment of patients with previously untreated MCL who would be eligible for auto-HSCT.
Source: lymphomahub.comCategories: General Medicine NewsTweet-
🚨 NEWS 🚨 The @EU_Commission has approved ibrutinib in combination with chemotherapy for the treatment of patients with previously untreated mantle cell lymphoma who would be eligible for auto-HSCT. Learn more: https://t.co/qZ1nkzthIP #lymphoma #lymsm #MedNews https://t.co/HRu9nFsrzW
-
-
Mashup Score: 2Tafasitamab in combination with rituximab and lenalidomide approved by the FDA for patients with R/R FL - 2 month(s) ago
On June 18, 2025, the FDA approved tafasitamab in combination with rituximab plus lenalidomide for the treatment of adult patients with R/R FL.
Source: lymphomahub.comCategories: General Medicine NewsTweet-
🚨 NEWS 🚨 @US_FDA approves tafasitamab in combination with rituximab plus lenalidomide for patients with R/R FL, based on results from the phase III inMIND trial. Learn more: https://t.co/xoYfAdLnBo #lymphoma #lymsm #MedNews https://t.co/vUwCFvlpR1
-
-
Mashup Score: 5FDA grants Breakthrough Therapy Designation to iopofosine I 131 for treatment of R/R WM - 3 month(s) ago
On June 4, 2025, the FDA granted Breakthrough Therapy Designation for iopofosine I 131 for the treatment of relapsed/refractory Waldenstrom’s macroglobulinemia.
Source: lymphomahub.comCategories: General Medicine NewsTweet-
The @US_FDA has granted Breakthrough Therapy Designation to iopofosine I 131 for treatment of R/R Waldenstrom’s macroglobulinemia: https://t.co/z6cfQkirbA #Lymphoma #LymSM #MedNews https://t.co/vhQm779JT4
-
-
Mashup Score: 14Brentuximab vedotin in combination with ECADD approved by the EC for patients with ND Stage IIb/III/IV Hodgkin lymphoma - 3 month(s) ago
On June 3, 2025, the European Commission approved brentuximab vedotin, in combination with ECADD chemotherapy, for adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma.
Source: lymphomahub.comCategories: General Medicine NewsTweet-
🚨 NEWS 🚨 The @EU_Commission approves brentuximab vedotin in combination with ECADD (BrECADD) for the treatment of newly diagnosed patients with Stage IIb/III/IV Hodgkin lymphoma. Learn more: https://t.co/VCKftCSMEc #lymphoma #lymsm #MedNews https://t.co/EkQrGPiHLz
-
-
Mashup Score: 4Brentuximab vedotin in combination with lenalidomide and rituximab receives U.S. FDA approval for the treatment of R/R LBCL - 6 month(s) ago
Following positive results from the phase III ECHELON-3 trial, the FDA approves brentuximab vedotin in combination with lenalidomide and rituximab, for the treatment of adult patients with R/R LBCL.
Source: lymphomahub.comCategories: General Medicine News, Oncologists1Tweet-
🚨 NEWS 🚨 @US_FDA approves brentuximab vedotin plus lenalidomide & rituximab for the treatment of adult pts with R/R LBCL after ≥2 lines of systemic therapy in those who are ineligible for auto-HSCT or CAR T-cell therapy. 👉 https://t.co/NZWy69X0r4 #lymphoma #lymsm #MedNews https://t.co/Ff5ofqo7Gy
-
-
Mashup Score: 3Lisocabtagene maraleucel receives positive CHMP opinion for the treatment of adult patients with R/R FL - 7 month(s) ago
Lisocabtagene maraleucel has received a positive CHMP opinion recommending its approval for patients with R/R FL, following positive results from the phase II TRANSCEND FL trial.
Source: lymphomahub.comCategories: General Medicine News, Oncologists1Tweet-
🚨NEWS 🚨 The EMA CHMP issued a positive opinion to liso-cel, a CD19-directed CAR T-cell therapy, for the treatment of adult patients with R/R FL after ≥2 prior systemic therapies, based on results from the TRANSCEND FL trial. 👉 https://t.co/hgpGPzrbSD #lymphoma #lymsm #MedNews https://t.co/CFqEQH0nvr
-
-
Mashup Score: 5
Following positive results from a phase I trial (NCT03081910), the FDA grants orphan drug designation to MB-105 for the treatment of relapsed/refractory T-cell lymphoma.
Source: lymphomahub.comCategories: General Medicine News, Oncologists1Tweet-
🚨 NEWS 🚨 The @US_FDA grants orphan drug designation to MB-105, a first-in-class autologous CD5-targeted CAR-T, for the treatment of patients with R/R T-cell #lymphoma, based on the results from a phase I trial (NCT03081910). Read more 👉 https://t.co/BkwKNiIa6A #lymsm #MedNews https://t.co/Adg1WMIzlj
-
🚨 News 🚨 The Korean Ministry of Food and Drug Safety (MFDS) approves axi-cel, a CD19-targeted CAR T-cell therapy, for the treatment of patients with R/R DLBCL and for patients with PMBCL. Read more: https://t.co/tz02J869Jg #lymphoma #lymsm #MedNews https://t.co/RoyT7lqo3u